
|Articles|February 15, 2004
QLT lowers verteporfin cost after CMS cuts reimbursement
Toronto-QLT Inc. is temporarily lowering the price of verteporfin (Visudyne, Novartis and QLT Inc.) by $55 after the Centers for Medicare & Medicaid Services (CMS) lowered the amount for which it would reimburse physicians.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Metformin use associated with reduced incidence of intermediate AMD
2
MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
3
Looking back at the 2025 EnVision Summit
4
Last year in glaucoma at EnVision Summit 2025
5




























